Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating

According to Tipranks, Truist told investors successful a probe enactment that it was revising estimates for YEZTUGO, a medicine cause to little HIV-1 risk, heading into fourth-quarter earnings. The steadfast is besides adjusting definite timelines pursuing caller updates connected upcoming launches, including BIC/LEN and Hepcludex successful the United States.

On the aforesaid day, Citigroup besides provided an update connected Gilead Sciences, Inc. (NASDAQ:GILD). The steadfast lifted its terms people connected the banal to $156 from $140, portion keeping a Buy rating.

Citi’s accommodation came arsenic portion of the firm’s broader Q4 preview of biopharmaceutical stocks. The slope expects achievable estimates and reduced argumentation hazard to make a promising situation for the radical this year.

Gilead Sciences, Inc. (NASDAQ:GILD) is simply a biopharmaceutical institution engaged successful the improvement of medicines to forestall and dainty assorted life-threatening diseases, including HIV, viral hepatitis, and cancer.

While we admit the imaginable of GILD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Defense Stocks to Buy successful the S&P 500 and 14 Best Booming Stocks to Buy Right Now.

Disclosure: None.